Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype A Case Report and Review of LiteratureSy, Andrew, MD; Cheng, Jerry, MD; Cooper, Robert, MD; Mueller, Lisa, MDJournal of Pediatric Hematology/Oncology: January 2019 - Volume 41 - Issue 1 - p e41–e43 doi: 10.1097/MPH.0000000000001230 Online Articles: Clinical and Laboratory Observations Abstract Author InformationAuthors Article MetricsMetrics Vincristine (VCR) is a common chemotherapeutic agent used in the treatment of multiple types of pediatric tumors. VCR’s adverse effects are well documented and commonly involve peripheral neuropathy via axonal degeneration. Neuropathic severity is dose-dependent, with sensory deficits occurring with as little as 4 mg cumulative dose. Severe peripheral neuropathy is generally rare, but its effects become additive when given to patients with undiagnosed hereditary peripheral neuropathy such as Charcot-Marie-Tooth. We report a case of an effect of VCR administration given to a patient who developed grade 4 neuropathy and was found to be a carrier of Charcot-Marie-Tooth disease type 4. Kaiser Permanente Southern California The authors declare no conflict of interest. Reprints: Andrew Sy, MD, 4700 Sunset Blvd., 3rd Floor Pediatrics, Los Angeles, CA 90027 (e-mail: email@example.com). Received July 5, 2017 Accepted May 1, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.